Research
Hormonal
In patients with type 2 diabetes duration greater than 10 years, GLP-1RA plus basal insulin fixed-ratio combinations (iDegLira, iGlarLixi) may be numerically more effective for HbA1c reduction than tirzepatide, suggesting tirzepatide is better suited for early-stage disease.
For patients with type 2 diabetes for more than 10 years, GLP-1RA plus basal insulin fixed-ratio combinations may offer better glycemic control than tirzepatide alone, making them a strong option for long-standing disease.
ModerateQualifiesMEDIUM confidence
in patients with a diabetes duration greater than 10 years, all doses of tirzepatide were numerically outranked by iDegLira and iGlarLixi... these findings suggest that tirzepatide could be preferentially considered for the management of early stages of type 2 diabetes... whereas GLP-1RA plus basal insulin FRC could be considered as an equally efficacious option in patients with longer disease duration.
Why this rating
Subgroup analysis of network meta-analysis; no significant differences were detected, only numerical trends.
Source
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Irene Caruso et al. · EClinicalMedicine · 2023
DOI 10.1016/j.eclinm.2023.102181
Meta-analysis · 40 studiesCited 51×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →